ArticleBritish journal of haematology2026
Circulating angiogenesis-related biomarkers in sickle cell retinopathy and maculopathy.
Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Sickle cell disease (SCD), encompassing genotypes such as HbSS and HbSC, leads to retinal complications such as sickle cell retinopathy (SCR) and maculopathy (SCM) through poorly understood mechanisms. This study explored associations of a panel of circulating angiogenesis-related factors with SCR and SCM. Adult HbSS (homozygous SCD; n = 33) and HbSC (compound heterozygous SCD; n = 33) patients underwent ophthalmic examination, including optical coherence tomography angiography, to assess SCR stage and presence of SCM. Plasma levels of circulating angiogenesis-related factors were analysed, with selected markers (angiopoietin-2, vascular endothelial growth factor [VEGF], granulocyte colony-stimulating factor, endoglin, endostatin, interleukin [IL]-6 and IL-10) assessed using enzyme-linked immunosorbent assay. Proliferative SCR (PSCR) was present in 5 (15.2%) HbSS and 21 (63.6%) HbSC patients. Foveal avascular zone abnormalities and macular thinning were present in 50.8% and 48.4% of patients respectively. Most vascular factors, including VEGF, showed no association with SCR or SCM. However, angiopoietin-2 was higher in HbSS patients, independent of SCR stage or SCM, and correlated with IL-6, IL-10, VEGF, reticulocyte counts, and lactate dehydrogenase (LDH). In HbSC patients, endostatin levels were highest in those with PSCR (p = 0.030). While most proteins were unrelated to retinal outcomes, angiopoietin-2 elevation may reflect HbSS-specific systemic hypoxia. Elevated endostatin in HbSC patients with PSCR suggests a potential role in PSCR development. These findings offer new leads for understanding SCD-related retinal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.